Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: A multicentre prospective study

European Heart Journal

Volumn 34, Issue 46, 2013, Pages 3580-3587

  Tribouilloy, Christophe ^a,b   Maréchaux, Sylvestre ^c   Jobic, Yannick ^d   Jeu, Antoine ^a   Ederhy, Stéphane ^e   Donal, Erwan ^f   Réant, Patricia ^g,h   Arnalsteen, Elise ⁱ   Boulanger, Jacques ^j   Garban, Thierry ^k   Ennezat, Pierre Vladimir ^l   Andréjak, Michel ^b   Rusinaru, Dan ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIV LILLE   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ Centre Hospitalier de Beauvais   (France)

^j Centre Hospitalier Compiegne   (France)

^k CHU de Nantes   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Benfluorex; Drug induced valvular disease; Echocardiography

Indexed keywords

BENFLUOREX;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCIBILITY; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; SMOKING; TREATMENT DURATION;

BENFLUOREX; DRUG-INDUCED VALVULAR DISEASE; ECHOCARDIOGRAPHY;

ANALYSIS OF VARIANCE; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; ECHOCARDIOGRAPHY; FEMALE; FENFLURAMINE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84890930990     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht266     Document Type: Article

References (29)

1. Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, Leroyer C. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE 2010;5:e10128.
2. Tribouilloy C, Rusinaru D, Henon P, Tribouilloy L, Leleu F, Andréjak M, Sevestre H, Peltier M, CausT. Restrictive organic mitral regurgitation associated with benfluorex therapy. Eur J Echocardiogr 2010;11: 614-621.
3. Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Marechaux S, Eicher JC, Blanchard-Lemoine B, Rousseau J, Henon P, Jobic Y, Etienne Y. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Eur J Echocardiogr 2011;12: 265-271.
4. Weill A, Païta M, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010;19: 1256-1262.
5. Derumeaux G, Ernande L, Serusclat A, Servan E, Bruckert E, Rousset H, Senn S, Van Gaal L, Picandet B, Gavini F, Moulin P, REGULATE Trail Investigators. Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS ONE 2012;7:e38273.
6. Tribouilloy C, Rusinaru D, Maréchaux S, Jeu A, Ederhy S, Donal E, Réant P, Arnalsteen E, Boulanger J, Ennezat P-V, Garban T, Jobic Y. Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus. A multicenter study. Circulation 2012;126: 2852-2858.
7. Fournier A, Zureik M. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in france. Pharmacoepidemiol Drug Saf 2012;21: 343-351.
8. Tribouilloy C, Rusinaru D, Andrejak M. How can benfluorex-related heart valve disease be identified by echocardiography? Arch Cardiovasc Dis 2011;104: 489-492.
9. Droogmans S, Kerkhove D, Cosyns B, Van Camp G. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10: 467-476.
10. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL. European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr 2010;11: 307-332.
11. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E, Monin JL, Pierard LA, Badano L, Zamorano JL. European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 2010;11: 223-244.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, StewartW, American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7: 79-108. (Pubitemid 43257193)
13. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009;374: 577-585.
14. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335: 609-616. (Pubitemid 26277950)
15. VanCampG, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with parkinson's disease treated with high-dose pergolide. Neurology 2003;61: 859-861. (Pubitemid 37174494)
16. Dupuy D, Lesbre JP, Gerard P, Andrejak M, Godefroy O. Valvular heart disease in patients with parkinson's disease treated with pergolide. Course following treatment modifications. J Neurol 2008;255: 1045-1048.
17. Droogmans S, Cosyns B, D'haenen H, Creeten E,Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, Van Camp G. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 2007;100: 1442-1445. (Pubitemid 47576024)
18. Tribouilloy C, Jeu A, Marechaux S, Jobic Y, Rusinaru D, Andrejak M. Benfluorex and valvular heart disease. Presse Med 2011;40: 1008-1016.
19. Boudes A, Lavoute Cc, Avierinos J-Fo, Le Dolley Y, Villacampa C, Salem A, Loundou AD, Michel N, Renard Sb, Habib G. Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease. Eur J Echocardiogr 2011;12: 688-695.
20. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134: 261-266.
21. Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34.
22. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283: 1703-1709. (Pubitemid 30196210)
23. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-2841.
24. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356: 6-9.
25. Cosyns B, Droogmans S, Rosenhek R, Lancellotti P. Drug-induced valvular heart disease. Heart 2013;99: 7-12.
26. Levy RJ. Serotonin transporter mechanisms and cardiac disease. Circulation 2006; 113: 2-4. (Pubitemid 43958480)
27. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337: 581-588. (Pubitemid 27360757)
28. Michopoulos V, Berga SL, Wilson ME. Estradiol and progesterone modify the effects of the serotonin reuptake transporter polymorphism on serotonergic responsivity to citalopram. Exp Clin Psychopharmacol 2011;19: 401-408.
29. Wust S, Kumsta R, Treutlein J, Frank J, Entringer S, Schulze TG, Rietschel M. Sexspecific association between the 5-HTT gene-linked polymorphic region and basal cortisol secretion. Psychoneuroendocrinology 2009;34: 972-982.